Interestingly, genomic and clinical data from 1961 AML patients analyzed via a machine learning process have been categorized as follows: combinations of mutated NPM1/wild-type IDH1-2, mutated NPM1/mutated IDH2, mutated NPM1/wild-type cohesin/mutated NRAS and mutated NPM1/mutated cohesin/mutated FLT3-ITD were categorized as good risk with a 60–80% 4-year OS, while the combination of mutated NPM1/mutated IDH1 was classified as intermediate risk with a 40–60% 4-year OS [93]. This evidence concerns the gene NRAS and acute myeloid leukemia.